Background: Percutaneous dilatational tracheostomy (PDT) has been considered as an alternative to surgical tracheostomy in intensive care units (ICU), and is widely used for critically ill patients who need prolonged mechanical ventilation. Few studies have reported on PDT performed in critically ill patients taking antiplatelet agents. Our goals are to assess not only the feasibility and safety of PDT, but also bleeding complications in the patients receiving such therapy. Methods: In a single institution, PDTs were performed by pulmonologists at the medical ICU bedside using the single tapered dilator technique and assisted by flexible bronchoscopy to confirm a secure puncture site. From March 2011 to February 2013, the patients' demographic and clinical data, procedural parameters, outcomes and complications were analyzed and compared complications between patients taking antiplatelet agents and those not. Results: PDTs were performed for 138 patients; the median age was 72 years, mean body mass index was 20.3 ± 4.8 kg/m 2 , and mean acute physiology and chronic health evaluation II score was 24.4 ± 9.4. Overall, the procedural success rate was 100% and the total procedural time was 25 ± 8.5 min. There were no periprocedural life-threatening complications, and no statistical difference in the incidence of bleeding complications between patients who had taken antiplatelet agents and those had not (p = 0.657). Conclusions: PDT performed in critically ill patients taking antiplatelet agents was a feasible procedure and was implemented without additional bleeding complications.
Introduction
Percutaneous tracheostomy was first performed in 1955 [1] after Seldinger's earlier description of a needle placement over a guide wire for arterial cannulation.[2] After Ciaglia's initial report of the dilatational technique in 1985, [3] percutaneous dilatational tracheostomy (PDT) has become a commonly performed procedure in intensive care units (ICUs). It has largely replaced conventional surgical tracheostomy in ICU patients, and provides benefits in terms of ease of performance, reduced complications, no need for additional transportation, and cost-effectiveness. [4, 5] Because PDT is a bedside procedure, it avoids the inconvenience of long waiting lists for operating room scheduling. With PDT there is a shorter delay between the time a decision is made to perform a tracheostomy and the time of the actual procedure. [6] Currently, the single tapered dilator (STD) with hydrophilic coating method has now appears to be the single most common technique for performing percutaneous tracheostomy. [7] [8] [9] In recent medical ICU, patients taking antiplatelet agents, which had become a crucial therapy for maintaining patency of vascular stents, increased due to cardiovascular or cerebrovascular comorbidities. Once the decision for PDT is made, it can be performed promptly at bedside without any significant delay associated discontinuing antiplatelet therapy. However, few studies have reported any evidence-based practical guidelines about whether stopping the agents or not before PDT performed in these patients until now. [10] The aim of this study is the feasibility and safety of PDT performed in critically ill patients, including especially who had taking antiplatelet agents, whether or not there is a risk of bleeding.
Materials and Methods
The study population (n = 138) was recruited from a medical ICU at a tertiary university hospital from March, 2011 to February, 2013 ( Fig. 1) . The patients' demographic and clinical characteristics were retrospectively reviewed and procedural data were analyzed. We also analyzed immediate complications as the primary outcome, including bleeding complications associated with antiplatelet agent regimens; and the clinical outcomes of longterm follow-ups during 6 months were also reviewed. This study 
Results
During the study period, 138 patients underwent PDT. Of the subjects, 94 were male (68.1%) with a median age of 72 years , and 81 (58.7%) of the patients were admitted to the ICU resulting from respiratory failure. PDT was performed 10.7 ± 8.5
days after endotracheal intubation. The baseline characteristics between antiplatelet groups are shown in Tables 1 and 2 .
All patients underwent successful procedures; no patient was unable to receive a tracheostomy tube. Vertical incisions were used in 109 cases (79.0%), and the incision size was 1.7 ± 0.4 cm.
Over the year, the total procedural time was shortened from 33 min to 22 min. Times were reduced from 32 to 20 min for two attending physicians, and from 43 to 23 min for four fellows who had their first PDT experience. However, there are no statistical difference in procedural time between attending physicians and fellows (p = 0.571).
Immediate complications are described in Table 3 . Overall complications occurred in 28 patients (20%); however, there were no periprocedural life-threatening complications and/or major bleeding (Table 3 ). There were minor bleedings in the antiplatelet group were only 2 (1.4%) patients. Noteworthy, there was no statistical difference in the incidence of bleeding complications between patients who had taken antiplatelet agents and those who had not (p = 0.657, Table 4 ).
Tracheostomy tubes were exchanged a week after PDT, and the mean follow-up duration was 120.6 days (Fig. 1) . (17) 2 (1) Values are presented as number (%). 
Discussion
PDT is considered to be a minimally invasive procedure that can be performed in the ICU at the patient's bedside. The time required for performing a bedside PDT is considerably shorter than that of open tracheostomy, [11] even performed by medical intensivisit or intensivist trainee, [12, 13] and the other advantages of PDT are as follows: it minimizes scheduling difficulties associated with the operating room and anesthesiology staff, does not require transporting critically ill patients to the operating room, and reduces the overall cost of the tracheostomy. For these reasons, PDT is presently a standard technique in critical care medicine and is usually considered as having a low risk of complications. [14, 15] In this study, we elucidated that 138 PDTs performed in a medical ICU were a feasible and safe procedure, especially in 26 critically ill patients even taking antiplatelet agents without increasing periprocedural complications. There was no statistical difference in the incidence of bleeding complications between patients who had taken antiplatelet agents and those who had not (p = 0.657). There are several reasons for low incidence of bleeding complications in this study; First of all, when all PDTs are performed under bronchoscopy assistance, we could perform PDT more accurately. Second, the minimal amount of skin incision required, with practically less bleeding observed. Third, before the procedure, we checked meticulously the anterior neck area around puncture site on the chest CT and did palpation using fingers for avoid aberrant vascular structures crossing the midline.
For this reason, in the recent study the use of ultrasound to evaluate cervical anatomy and to guide puncture in real-time has been advocated to improve safety and efficacy of PDT. [16, 17] In our study, the overall procedural success rate was 100%, and the mean total procedural time was 25 min; it was shortened as the operators became more experienced (33 min in 2011, 22 min in 2012). This result demonstrates that PDT procedures have educational merit, even for first-year fellows, based on non-surgical training experience from instructors such as pulmonologists.
Undoubtedly, bronchoscopy assistance results in PDT being an easier procedure.
In our study population, there were two patients who can be safely performed with PDT even taking dual antiplatelet therapy. mm. Nevertheless, there was no problem securing upper airway patency after long-term follow-up, regardless of whether decannulation was performed or not, there seen only mild scarring at the decannulated PDT site externally and on the endobronchial side inspected by bronchoscopy (Fig. 2) .
However, the present study has several limitations. First, this study was conducted at a single center with not much PDT patient experience compared to abroad big hospitals. However, in Asia, and particularly in developing countries, there are few studies like this study. Second, while a study reporting on the associations of bleeding tendencies with the use of antiplatelet agents is new, it is a retrospective study, so a randomized, controlled trial is needed to confirm the findings. Third, in Korea, medical costs in the ICU are not properly reflected when a surgical tracheostomy is performed, considering the expenses incurred from the additional costs resulting from increased lengths of stays on the ICU.
More multicenter studies about PDT as a treatment tool in accordance with the cost of complications, including comparative effectiveness are needed.
In conclusion, PDT performed in critically ill patients taking antiplatelet agents was a feasible and implementable procedure without additional bleeding complications.
